Tenon Medical (TNON) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
13 Jul, 2026Voting matters and shareholder proposals
Majority of voting power present or represented by proxy is required to approve the Auditor Appointment, Debt Financing, Future Financings, and Reverse Stock Split Proposals; abstentions count as votes against these proposals.
Majority of votes cast is required for the Adjournment Proposal; abstentions have no effect on this proposal.
Brokerage firms have discretionary authority to vote unvoted shares on the Auditor Appointment and Reverse Stock Split Proposals, but not on other proposals.
Broker non-votes have no effect on non-routine proposals.
Audit committee and external auditor matters
Stockholder ratification is not required for the appointment of the independent registered public accounting firm, but if not ratified, the audit committee will reconsider the appointment.
Haskell and White LLP is proposed as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
Latest events from Tenon Medical
- Q2 revenue up 21%, gross margin at 52%, but going concern risk remains.TNON
Q2 20248 Jul 2026 - Raising up to $3.5M via shares and warrants to fund growth, repay debt, and address Nasdaq compliance.TNON
Registration filing26 Jun 2026 - Board seeks approval for director elections, reverse stock split, and key financing proposals.TNON
Proxy filing23 Jun 2026 - IPO offers shares and warrants to fund expansion, repay debt, and support R&D amid Nasdaq risks.TNON
Registration filing22 Jun 2026 - Registering 6.3M shares for resale, company targets SI joint market but faces dilution and going concern risks.TNON
Registration filing22 Jun 2026 - Shareholders will vote on director elections, a reverse stock split, and key financing approvals.TNON
Proxy filing12 Jun 2026 - Q1 2026 revenue up 90% to $1.4M, gross margin 68.5%, net loss narrowed, liquidity risks remain.TNON
Q1 202615 May 2026 - Record revenue, margin gains, and new product launches drive growth and improved financials.TNON
Q4 202520 Mar 2026 - Innovative SI joint fusion tech shows strong results and expands with new miniaturized platform.TNON
Maxim Group’s 2024 Healthcare Virtual Summit19 Jan 2026